Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of lymphoplasmacytic lymphoma including patients with Waldenstrom's macroglobulinemia~* Adequate organ function: ANC \> 500/ul; PLT \> 25,000/ul; serum creatinine \< 2.5; serum total bilirubin and SGOT \< 2.5 times the upper normal limit.~* Age greater than 18 years~* Life expectancy of 6 months or greater~* ECOG performance status of 0-2~Exclusion Criteria:~* Chemotherapy, steroid therapy, or radiation therapy within 21 days of study entry.~* Prior Campath-1H or monoclonal antibody therapy within 3 months of study entry.~* Pregnant women~* Serious co-morbid disease, uncontrolled bacterial, fungal, or viral infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Campath-1H (Type: EXPERIMENTAL): 30 mg IV three times a week, 6-12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).